Key Summary Points {#FPar1}
==================

**Why carry out this study?**The clinical efficacy of intravitreously administered Conbercept (IVC) has been reported in some prospective and retrospective studies to date. However, the evidence on efficacy of IVC monotherapy for DME was still limitedWhat was the evidence-based efficacy of IVC monotherapy for DME?**What was learned from the study?**Our findings suggest improved VA and CMT outcomes during 1-year follow-up in patients with DME who underwent IVC monotherapyIncreased injection frequency demonstrates a significant trend with improved outcomes at 12 monthsIVC monotherapy as the initial treatment might be a treatment option for DME

Introduction {#Sec1}
============

Currently, the prevalence of diabetes mellitus (DM) is rapidly increasing worldwide. Among the complications of diabetes, the most common diabetic eye disease is diabetic retinopathy (DR), and DR is also the most common cause of blindness in working-age populations in developed countries \[[@CR1], [@CR2]\]. Among patients with DR, visual function can be severely damaged by diabetic macular edema (DME), which is one of the most common complications of DR and significantly affects the quality of life among patients with diabetes \[[@CR3]\].

DME is caused by the destruction of the internal and external barrier functions of the retinal blood vessels, leading to the extravasation of fluid and lipoproteins into the macular area \[[@CR3]\]. Vascular endothelial growth factor (VEGF) has been shown to be the key promoter of damage to the blood-retinal barrier by increasing vascular permeability, leakage of retinal microvessels, and accumulation of retinal fluid in the macular region, which is currently the main pathogenesis of DME \[[@CR4], [@CR5]\]. Hence, the treatment strategy for DME has focused on anti-VEGF therapy, and intravitreal injection with an anti-VEGF agent has emerged as the first-line therapy for DME. There are a variety of anti-VEGF agents in the clinic such as bevacizumab (Avastin^®^) and ranibizumab (Lucentis^®^), which have been found to bind VEGFA only, or both; in addition, aflibercept (Eylea^®^), which is composed of the second domain of human VEGF receptor (VEGFR)-1 and the third domain of VEGFR-2, fused to the Fc domain of human immunoglobulin 1 (IgG1).

Conbercept (KH902; Chengdu Kanghong Biotech Co., Ltd., Sichuan, China), as a recent novel VEGF antagonist, is a 143-kDa humanized recombinant anti-VEGF fusion protein, consisting of extracellular domain 2 of VEGFR-1 and domains 3 and 4 of VEGFR-2, which bind to the Fc domain of human IgG1, and is a soluble receptor decoy that blocks all isoforms of VEGFA, VEGFB, VEGFC, and placenta growth factor (PIGF) \[[@CR6]\]. Conbercept can effectively antagonize the effects of VEGF. It has the advantages of multiple targets, strong affinity, and a long half-life in vitreous \[[@CR7], [@CR8]\]. Previous studies revealed that intravitreally administered Conbercept (IVC) could significantly improve the vision and reduce central macular thickness (CMT) of patients with DME \[[@CR9], [@CR10]\]. However, these studies were conducted in single centers with small sample sizes and the results have not been systematically collected, sorted, or evaluated. Recently, a meta-analysis was performed to evaluate the efficacy of intravitreally administered ranibizumab (IVR) and IVC in patients with DME \[[@CR11]\]. To date, no systematic review has reported on the effect and safety of IVC monotherapy in patients with DME. We performed a systematic review and meta-analysis to quantify the effect of IVC monotherapy on best corrected visual acuity (BCVA) and CMT in patients with DME.

Methods {#Sec2}
=======

Our systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR12]\].

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

The present study is based on previously reports and does not contain any studies with human participants or animals performed by any of the authors.

Search Strategy, Inclusion Criteria, Exclusion Criteria, and Data Collection {#Sec4}
----------------------------------------------------------------------------

We performed a comprehensive systematic literature search using Pubmed, ClinicalTrials.gov, EMbase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedicine Literature Database (CBM-SinoMed), Chin VIP Information (VIP) Database for Chinese Technical Periodicals, and Wanfang Database for articles written in English or Chinese and published up to November 2019, and the references of all included studies were also traced. The search terms used were: "conbercept" OR "anti-VEGF" OR "anti-vascular endothelial growth factor" OR "Lumitin" OR "KH902" AND "diabetic macular edema" OR "diabetic macular oedema". Two authors, TTN and JSG, assessed all eligible studies and data independently. A consensus was reached if there were any cases of disagreement.

The inclusion criteria were studies that (1) provided sufficient data for a comparison of pre- and post-treatment BCVA and CMT of patients with DME given IVC; (2) human studies available in English or Chinese.

The exclusion criteria were (1) patients with DME received more than one type of therapy rather than IVC separately; (2) no sufficient data was available on the variation change in BCVA or CMT, e.g., the mean, standard deviation, or standard error; (3) animal or cell research, non-original research (reviews, editorials, or comments), abstracts, unpublished studies, and duplicated studies.

The primary outcome of this systematic analysis focused on assessing the effect of IVC therapy on BCVA and CMT from baseline to 1, 3, 6, or 12 months of treatment for DME. Additional outcomes included the relationship between the number of IVC injections and change in outcome, as well as the complications and serious adverse events (SAEs). BCVA was obtained using the logarithm of the minimum angle of resolution (logMAR) and Early Treatment Diabetic Retinopathy Study (ETDRS). CMT was demonstrated on optical coherence tomography (OCT).

Data Extraction and Risk of Bias Assessment {#Sec5}
-------------------------------------------

The relevant data from the articles were extracted using a standard data extraction form. The extracted data included the first author(s), publication date, study design, sample size, age, sex, interventions details, and follow-up periods. The literature quality was evaluated by using the Jadad scores (ranging from 0 to 5) \[[@CR13]\]. Studies with a score of at least 3 were considered to be "high quality" studies.

Statistical Analysis {#Sec6}
--------------------

The meta-analyses were performed using the DerSimonian--Laird random-effects method regardless of the amount of heterogeneity between studies. The standardized mean difference (SMD) or weighted mean difference (WMD) with a 95% confidence interval \[CI\] was used to assess continuous variable outcomes. Heterogeneity between studies was based on the size of the *I*^2^ value. Substantial heterogeneity was assumed if the *I*^2^ value was above 50%. Meta-regression was used to examine the relationship in the various studies between the number of injections, baseline CMT, and the change in outcomes. Some studies provided data on different follow-up subgroups, rather than the same follow-up time. For these studies, each subgroup was regarded as a separate study in all analyses. STATA 11.0 software was applied to integration analysis. A *P* value less than 0.05 was considered to be statistically significant.

Results {#Sec7}
=======

Study Selection {#Sec8}
---------------

There were 91 articles identified for the initial review. After further examination of all files, 42 articles satisfied the available information on BCVA and/or CMT, then these files went through a full-text review. After excluding studies which were not original regarding articles, we included 20 studies \[[@CR9], [@CR10], [@CR14]--[@CR31]\] (1244 participants, 1278 eyes) in this meta-analysis. The selection of studies is shown in the PRISMA flow diagram in Fig. [1](#Fig1){ref-type="fig"}. The characteristics of the 20 included studies are provided in Table [1](#Tab1){ref-type="table"}.Fig. 1Eligibility of studies for inclusion in meta-analysisTable 1Characteristics of including studiesNo.Author (year)Study designDM typeDME typeAge (mean ± SD/range, years)Male/female (*N*)Patients (*N*)Eyes (*N*)No. of injections, mean (SD)Treatment regimenJadad score1Liu et al. (2019) \[[@CR14]\]RetrospectiveType 2DME53.9 (34--69)10/313263Monthly × 332Li et al. (2019) \[[@CR15]\]RetrospectiveNADME50.5 ± 3.3 (44--62)24/2650503Monthly × 333Chang et al. (2016) \[[@CR16]\]RetrospectiveNACSME49--6211/1021223.051 + PRN34Jiang et al. (2017) \[[@CR17]\]ProspectiveType 2CSME/CME/DDME54.10 ± 10.6512/820203.20 ± 0.523 + PRN45Guo et al. (2018) \[[@CR18]\]RetrospectiveNADME61.35 ± 7.5828/2755553Monthly × 336Zhang et al. (2018) \[[@CR19]\]ProspectiveNADDME51.88 ± 10.1813/1225251Monthly × 147Sun et al. (2018) \[[@CR20]\]ProspectiveNADME66.52 ± 8.3913/1629303Monthly × 338Zhang et al. (2018) \[[@CR21]\]ProspectiveNADDME51.90 ± 10.90NA17173Monthly × 339Ren et al. (2019) \[[@CR22]\]ProspectiveNADDME59.24 ± 8.61NA35351Monthly × 13NACME62.51 ± 9.1233331Monthly × 1NASRD60.86 ± 9.4728281Monthly × 110Li et al. (2019) \[[@CR23]\]RetrospectiveNADME54 ± 524/1619211Monthly × 1411Zhang et al. (2019) \[[@CR24]\]ProspectiveNADMENA17/2340403Monthly × 3312Xu et al. (2016) \[[@CR25]\]RetrospectiveType 1/Type 2DDME60.9 ± 12.912/1426315.6 ± 0.81 + PRN313Qian (2017) \[[@CR26]\]RetrospectiveNADDMENANA33405.8 ± 1.71 + PRN314Xu et al. (2017) \[[@CR27]\]RetrospectiveType 1/Type 2CSME/DDME61.3 ± 14.918/1432366.6 ± 0.93 + PRN315Li et al. (2018) \[[@CR28]\]RetrospectiveNADDMENA28/4620203.20 ± 0.41 + PRN3CME36363.39 ± 0.951 + PRNSRD18184.22 ± 1.551 + PRN16Li et al. (2017) \[[@CR10]\]RetrospectiveType 2DME59.8 ± 9.8NA37376.741 + PRN3NADME54.4 ± 6.3NA25256.51 + PRN17Niu and Ji (2018) \[[@CR29]\]ProspectiveType 2DME52.8 ± 14.015/8232321 + PRN318Xu et al. (2019) \[[@CR30]\]RetrospectiveNACSME60.55 ± 8.6510/1020206.60 ± 3.023 + PRN319Zhou et al. (2019) \[[@CR9]\]RetrospectiveNADME59.6 ± 8.546/4360604.5 ± 1.03 + PRN320Li et al. (2019) \[[@CR31]\]ProspectiveNADME60.6 ± 12.319/1332328.58 ± 2.43 + PRN4*CSME* clinical significant macular edema, *CME* cystoid macular edema, *DME* diabetic macular edema, *DDME* diffuse diabetic macular edema, *SRD* serous retinal detachment, *PRN* pro re nata, *NA* not applicable

Change in BCVA {#Sec9}
--------------

Table [2](#Tab2){ref-type="table"} shows that compared with baseline data, logMAR BCVA scale was significantly improved at 1, 3, 6, and 12 months after IVC injection \[SMD − 1.24 (− 2.09 to − 0.38, *P* \< 0.001); − 2.30 (− 3.37 to − 1.23, *P* \< 0.001); − 1.98 (− 2.88 to − 1.08, *P* \< 0.001), and − 0.67 (− 1.11 to − 0.24, *P* \< 0.001)\]. Similar results were found to allow a quantitative synthesis that ETDRS BCVA scale was significantly improved at 1, 3, 6, 9, and 12 months after IVC injection \[SMD 0.55 (0.11--0.98, *P* = 0.014); 0.56 (0.17--0.95, *P* = 0.005); 0.64 (0.31--0.97, *P* \< 0.001); 0.51 (0.01--1.00, *P* = 0.046), and 1.03 (0.69--1.38, *P* \< 0.001)\]. There was still no evidence on the effects of IVC injection for DME with logMAR scale at 9 months and ETDRS scale at 2 months. Evidence of heterogeneity is shown in Table [2](#Tab2){ref-type="table"}. A summary of the publication bias assessment using the Begg's and Egger's tests is provided in Table [3](#Tab3){ref-type="table"}.Table 2Pooled visual acuity changes in patients with DME by IVC injection during 1-year follow-upSubgroup restrictionFollow-up timeNumber of studiesVisual testing scalePooled visual change (95% CI)*PI*^2^ (%)*P*~heterogeneity~Retrospective1 month3logMAR− 3.33 (− 5.83, − 0.84)0.00997.2\< 0.001Prospective1 month6logMAR− 0.38 (− 0.90, 0.15)0.15981.3\< 0.001Overall pooling1 month9logMAR− 1.24 (− 2.09, − 0.38)0.00594.7\< 0.001Retrospective2 months2logMAR− 3.25 (− 8.07, 1.56)0.18597.5\< 0.001Prospective2 monthsNAlogMARNANANANAOverall pooling2 months2logMAR− 3.25 (− 8.07, 1.56)0.18597.5\< 0.001Retrospective3 months4logMAR− 6.09 (− 10.53, − 1.65)0.00798.6\< 0.001Prospective3 months9logMAR− 0.77 (− 1.38, − 0.17)0.01289.3\< 0.001Overall pooling3 months13logMAR− 2.30 (− 3.37, − 1.23)\< 0.00197\< 0.001Retrospective6 months3logMAR− 8.58 (− 17.50, 0.34)0.05999.2\< 0.001Prospective6 months10logMAR− 0.72 (− 1.29, − 0.15)0.01389.3\< 0.001Overall pooling6 months13logMAR− 1.98 (− 2.88, − 1.08)\< 0.00196.4\< 0.001Retrospective9 monthsNAlogMARNANANANAProspective9 monthsNAlogMARNANANANAOverall pooling9 monthsNAlogMARNANANANARetrospective12 months1logMAR− 0.33 (− 0.68, 0.033)0.075NANAProspective12 months4logMAR− 0.79 (− 1.33, − 0.24)0.00569.50.02Overall pooling12 months5logMAR− 0.67 (− 1.11, − 0.24)0.00369.50.01Retrospective1 month1ETDRS0.48 (− 0.116, 1.08)0.114NANAProspective1 month1ETDRS0.62 (− 0.02, 1.25)0.058NANAOverall pooling1 month2ETDRS0.55 (0.11, 0.98)0.01400.768Retrospective2 monthsNAETDRSNANANANAProspective2 monthsNAETDRSNANANANAOverall pooling2 monthsNAETDRSNANANANARetrospective3 monthsNAETDRSNANANANAProspective3 months2ETDRS0.56 (0.17, 0.95)0.00500.374Overall pooling3 months2ETDRS0.56 (0.17, 0.95)0.00500.374Retrospective6 months1ETDRS0.63 (0.03, 1.23)0.041NANAProspective6 months2ETDRS0.64 (0.25, 1.04)0.00100.356Overall pooling6 months3ETDRS0.64 (0.31, 0.97)\< 0.00100.653Retrospective9 months0ETDRSNANANANAProspective9 months1ETDRS0.51 (0.01, 1.00)0.046NANAOverall pooling9 months1ETDRS0.51 (0.01, 1.00)0.046NANARetrospective12 months6ETDRS1.12 (0.77, 1.48)\< 0.00161.40.024Prospective12 months1ETDRS0.51 (0.01, 1.01)0.044NANAOverall pooling12 months7ETDRS1.03 (0.69, 1.38)\< 0.00161.40.008*DME* diabetic macular edema, *ETDRS* Early Treatment Diabetic Retinopathy Study, *IVC* intravitreally administered Conbercept, *logMAR* logarithm of the minimum angle of resolution, *NA* not applicable (no analysis performed because of an insufficient number of studies providing data), *CI* confidence intervalTable 3Overall publication bias testing by Begg's test and Egger's testItemsFollow-up timeBegg's testEgger's testlogMAR BCVA scale1 month0.6770.3442 monthsNA0.3173 months0.110.0166 months0.180.049 monthsNANA12 months0.140.74ETDRS BCVA scale1 month0.32NA2 monthsNANA3 months0.32NA6 months0.120.369 monthsNANA12 months0.650.11CMT1 month0.480.0492 months0.32NA3 months0.24\< 0.0016 months0.210.049 monthsNANA12 months0.170.28*ETDRS* Early Treatment Diabetic Retinopathy Study, *logMAR* logarithm of the minimum angle of resolution, *CMT* central macular thickness, *NA* not applicable (no analysis performed because of an insufficient number of studies providing data)

Change in CMT {#Sec10}
-------------

The pooled results of the overall and subgroup by study design effects of IVC on changes in CMT at 1, 2, 3, 6, 9, and 12 months are shown in Table [4](#Tab4){ref-type="table"}. The results from the various studies suggest that the overall CMT decrease was 141.48 µm (89.81--193.15, *P* \< 0.001) at 1 month, 287.02 µm (251.71--322.34, *P* \< 0.001) at 2 months, 182.70 µm (150.44--214.96, *P* \< 0.001) at 3 months, 219.53 µm (165.33--273.73, *P* \< 0.001) at 6 months, 113.40 µm (53.27--173.53, *P* \< 0.001) at 9 months, and 142.79 µm (112.71--172.87, *P* \< 0.001) at 12 months. Evidence of heterogeneity is shown in Table [4](#Tab4){ref-type="table"}. A summary of the publication bias assessment using the Begg's and Egger's test is provided in Table [3](#Tab3){ref-type="table"}.Table 4Pooled central macular thickness changes in patients with DME by IVC injection during 1-year follow-upSubgroup restrictionFollow-up timeNumber of studiesPooled visual change (95% CI)*PI*^2^ (%)*P*~heterogeneity~Retrospective1 month5− 213.92 (− 295.78, − 132.06)\< 0.00192.3\< 0.001Prospective1 month6− 76.565 (− 97.29, − 55.84)\< 0.00120.40.28Overall pooling1 month11− 141.48 (− 193.15, − 89.81)\< 0.00193.1\< 0.001Retrospective2 months2− 287.02 (− 322.34, − 251.71)\< 0.00100.951Prospective2 monthsNANANANANAOverall pooling2 months2− 287.02 (− 322.34, − 251.71)\< 0.00100.951Retrospective3 months5− 212.22 (− 289.28, − 135.16)\< 0.00197.7\< 0.001Prospective3 months11− 168.80 (− 202.89, − 134.71)\< 0.00184.5\< 0.001Overall pooling3 months16− 182.70 (− 214.96, − 150.44)\< 0.00194.2\< 0.001Retrospective6 months5− 223.29 (− 330.63, − 115.95)\< 0.00197.5\< 0.001Prospective6 months11− 217.36 (− 278.02, − 156.71)\< 0.00195.4\< 0.001Overall pooling6 months16− 219.53 (− 273.73, − 165.33)\< 0.00196.6\< 0.001Retrospective9 monthsNANANANANAProspective9 months1− 113.40 (− 173.53, − 53.27)\< 0.001NANAOverall pooling9 months1− 113.40 (− 173.53, − 53.27)\< 0.001NANARetrospective12 months6− 160.82 (− 200.14, − 121.50)\< 0.00177.6\< 0.001Prospective12 months6− 123.89 (− 165.55, − 82.23)\< 0.00179.0\< 0.001Overall pooling12 months12− 142.79 (− 172.87, − 112.71)\< 0.00180.8\< 0.001*DME* diabetic macular edema, *IVC* intravitreally administered Conbercept, *NA* not applicable (no analysis performed because of an insufficient number of studies providing data), *CI* confidence interval

Injection Frequency and BCVA Outcomes {#Sec11}
-------------------------------------

Table [5](#Tab5){ref-type="table"} shows meta-regression results on the number of IVC injections for logMAR and ETDRS BCVA scale gain at 1, 3, 6, 9, and 12 months, which suggested a significant relationship with change in logMAR BCVA score at 12 months (Fig. S1 in the electronic supplementary material). An increase of one injection was associated with an increase of 1.19 (0.34--2.35, *P* = 0.04) logMAR BCVA score. However, a greater number of injections was not associated with a significant change in ETDRS BCVA scale at either 6 or 12 months. Insufficient data were available to properly evaluate this relationship at either 2 or 9 months for logMAR BCVA scale and at 1, 2, 3, or 9 months for ETDRS BCVA scale.Table 5Meta-regression results for association between number of injections and visual acuity gainVisual acuity testing scaleFollow-up timeNumber of studiesCoefficient (95% CI)*P*Adjusted *R*^2^logMAR1 month9− 0.16 (− 2.01, 1.68)0.8417.09%2 monthsNANANANA3 months130.01 (− 1.79, 1.81)0.999.61%6 months13− 0.04 (− 2.66, 2.57)0.9710.08%9 monthsNANANANA12 months6− 1.19 (− 2.35, − 0.34)0.04100%ETDRS1 monthNANANANA2 monthsNANANANA3 monthsNANANANA6 months30.05 (− 0.74, 0.84)0.60%9 monthsNANANANA12 months70.13 (− 0.42, 0.69)0.5620.79%*ETDRS* Early Treatment Diabetic Retinopathy Study, *logMAR* logarithm of the minimum angle of resolution, *NA* not applicable (no analysis performed because of an insufficient number of studies providing data), *CI* confidence interval

Injection Frequency and CMT Outcomes {#Sec12}
------------------------------------

The association between the number of IVC injections and the change in CMT within patients with DME at 1, 3, 6, and 12 months was examined by meta-regression (Table [6](#Tab6){ref-type="table"}). The number of IVC injections had a significant impact on the change in CMT at 12 months, but the association was not deemed significant at 1, 3, or 6 months. An increase of one IVC injection was associated with a mean 20.26 µm (0.87--39.66, *P* = 0.04) decrease in CMT (Fig. S2 in the electronic supplementary material).Table 6Meta-regression results for association between number of injections and CMT gainCovariableFollow-up timeNumber of studiesCoefficient (95% CI)*P*Adjusted *R*^2^CMT1 month11− 19.81 (− 81.77, 42.14)0.496.04%2 monthsNANANANA3 months16− 15.04 (− 55.96, 25.87)0.444.14%6 months16− 3.78 (− 65.77, 58.19)0.897.41%9 monthsNANANANA12 months12− 20.26 (− 39.66, − 0.87)0.0436.85%*CMT* central macular thickness,*NA* not applicable (no analysis performed due to an insufficient number of studies providing data), *CI* confidence interval

Adverse Effects (AEs) {#Sec13}
---------------------

According to systematic review, patients with DME after IVC injection experienced ocular adverse events including conjunctival hemorrhage (*n* = 29), intraocular pressure increase (*n* = 7), transient anterior chamber inflammatory activity (*n* = 3), vitreous floaters (*n* = 1), vitreous hemorrhage (*n* = 1), and corneal abrasion (*n* = 1).

Discussion {#Sec14}
==========

In this systematic review and meta-analysis, a total of 20 papers involving 1244 patients with DME were included. After pooled analysis, we found that IVC monotherapy led to significant visual acuity and CMT improvement in the treatment of DME. A significant relationship was found between the number of IVC injections and change in logMAR BCVA scale and CMT at 12 months. In addition, no serious AEs caused by the IVC injection were found.

Conbercept has been produced by the expression system of Chinese hamster ovary (CHO) cells and combines placental growth factor (PIGF) and all isoforms of VEGFA as well as VEGFB. Conbercept is alike in structure to aflibercept (Eylea, Regeneron Pharmaceuticals, Eastview, NY, USA). Many single-center, small-sized clinical trials showed that IVC injection for treatment of DME is significantly better than baseline in improving vision. Additionally, Conbercept has received marketing authorization in May 2019 by the China State Food and Drug Administration (CFDA) for the therapy of DME. As far as clinical practice is concerned, some patients with DME who were nonresponsive to intravitreal ranibizumab and bevacizumab therapy were still able to undergo effective treatment with Conbercept \[[@CR32]\]. Nonetheless, large-scale, standard, and stringently controlled clinical trials are necessary to confirm these findings.

Previously, clinical trials on intravitreal anti-VEGF agent monotherapy in patients with DME showed that the mean improvement in BCVA was 0.81 logMAR after 3 months of treatment \[[@CR33]\], and 0.3--3.85 logMAR after 12 months of treatment \[[@CR34]--[@CR36]\]. Our analysis of IVC monotherapy showed a mean logMAR BCVA scale improvement in which the largest change (6.09 logMAR) occurred at 3 months after treatment among retrospective studies (*n* = 4), which was higher than that previously reported. For ETDRS BCVA scale, the mean improvement with anti-VEGF agents was reported to be in the range of 5--13 letters after 12 months of treatment \[[@CR34], [@CR37]--[@CR39]\]. Our results found that the largest mean change of ETDRS BCVA score was 1.12 (0.77--1.48) after pooling retrospective studies (*n* = 6), which was below the lower ends of the range of previous reports.

Additionally, there was some significant heterogeneity between included studies. This discrepancy could have occurred as a result of the heterogeneity of patient characteristics such as age and disease severity, comorbidities, methods for diagnosis and evaluation, treatment doses and interval, and study design features \[[@CR40]--[@CR43]\].

In a real-life clinical practice study, after 12-month follow-up, both IVC and IVR injection achieved similar clinical efficacy in the treatment of DME. However, in comparison to the IVR arm, IVC showed a longer treatment interval and fewer injections were needed \[[@CR27]\]. Currently, there is still no evidence on the correlation between trends of efficacy and the number of IVC injections for DME. Hence, our meta-regression results revealed that there is a correlation between the frequency of IVC injections and efficacy (i.e., visual acuity gain and CMT decrease). We found that an increase of one injection was associated with an increase of 1.19 logMAR BCVA score at 12-month follow-up. The improvement in vision persisted till 12 months after first injection and the response had a dose--effect relationship between number of injections and visual gain. As a strong predictor of anatomical and functional outcome, CMT provides a measure of retinal recovery after treatment. Notably, our meta-analysis showed a significant decrease in CMT in patients with DME who underwent IVC injection. A significant effect was observed at 12-month follow-up, when an increase of one injection was associated with a 20.26-µm decrease in CMT.

According to the AEs reports, IVC injection was safe and well tolerated in the clinic. The ocular AEs were typical of complications with intravitreal injections such as intraocular pressure increase, conjunctival hemorrhage, etc. There were no reports of systemic AEs. The true incidence of ocular or systemic AEs requires a large-scale, real-life trial or observation for further assessment.

A strength of this study was that is was the first meta-analysis to evaluate the effect and safety of IVC injection for patients with DME. However, there were some limitations in this study: (1) As Conbercept has not yet been approved outside China, only Chinese patients were enrolled; (2) there were different follow-up times for observation; (3) only English or Chinese publications were evaluated; (4) there are no unpublished results; thus, publication bias cannot be fully excluded; (5) as the heterogeneity between study results was significant, it could be regarded as a weakness of the study. Multicenter, large-sample, double-blind randomized controlled trials are still needed to verify our findings.

Conclusions {#Sec15}
===========

In summary, the current systematic review and meta-analysis revealed that IVC injection alone was effective in the treatment of DME during 1-year observation. An increase of one injection was associated with an increase of 1.19 logMAR BCVA score and a decrease of 20.26 µm in CMT at 12-month follow-up. The current systematic review and meta-analysis showed that IVC monotherapy had significant visual and CMT outcomes in the treatment of DME.
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